Company: ERAS
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103868
Chunk: 37

Company: Erasca, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 37
---
 to forgo and did not receive. |

| (3) | Represents matching contributions under our 401(k) plan earned by the NEOs in 2024 and, for Drs. Lim and Chacko, in 2023, which are expected to be made by us on behalf of the NEOs in 2025 and 2024, respectively. |

Narrative disclosure to compensation tables The primary elements of compensation for our NEOs are base salary, annual performance bonuses and equity awards. The NEOs also participate in employee benefit plans and programs that we offer to our other employees, as described below. Annual base salary We pay our NEOs a base salary to compensate them for the satisfactory performance of services rendered to us. The base salary payable to each NEO is intended to provide a fixed component of compensation reflecting the executive’s skill set, experience, role and responsibilities. Base salaries for our NEOs have generally been set at levels deemed necessary to attract and retain individuals with superior talent. 24

Effective January 1, 2024, Dr. Lim’s annual base salary was increased from $622,800 to $644,600, Dr. Chacko’s annual base salary was increased from $475,500 to $492,100, and Dr. Morris’ annual base salary was increased from $470,000 to $486,500. In February 2025, each of Drs. Lim, Chacko, and Morris received a base salary increase to $670,400, $516,700, and $515,000, respectively, effective January 1, 2025. We expect that base salaries for our NEOs will be reviewed periodically by our Compensation Committee, with adjustments expected to be made generally in accordance with the considerations described above and to maintain base salaries at competitive levels. Bonus compensation From time to time, our Board or Compensation Committee may approve bonuses for our NEOs based on individual performance, company performance, or as otherwise determined appropriate. Pursuant to their respective employment letter agreements, each NEO has an established target annual bonus amount. For 2024, our NEOs’ target bonuses, expressed as a percentage of annual base salary, were 60% for Dr. Lim and 40% for Drs. Chacko and Morris. For 2024, annual bonuses were based on corporate performance relative to key corporate objectives tied to clinical and regulatory priorities as well as operational and financial objectives. Following a comprehensive review of our corporate performance relative to these corporate objectives, our compensation committee